

# Product Sheet



# QVQ

QUALITY IN ANTIBODIES

Yalelaan 1  
3584 CL Utrecht  
The Netherlands  
+31 30 253 3421


www.qvquality.com  
KvK: 30274082  
VAT: 8215.17.168  
NL88 RABO0153194936

## CXC chemokine receptor type 4 (CXCR4) / fusin

**Catalogue no.:** Q85c  
**Clone name:** QX4-E11 / VUN401

**Product:** VHH directed against CXCR4

**Target:** The CXC chemokine receptor type 4 (CXCR4 / fusin, UniProtKB P61073) is a 7-transmembrane spanning class A (rhodopsin-like) G protein-coupled receptor (GPCR). Binding of the chemokine CXCL12/SDF1 $\alpha$  activates heterotrimeric Gai, promoting cytoskeleton rearrangements and migration of e.g. immune cells to sites of inflammation. CXCR4 is important during embryonic development and regulates the homing and retention of hematopoietic stem cells in bone marrow. Upregulation of CXCR4 and CXCL12 contributes to the progression and metastasis of many tumor types. In addition, CXCR4 acts as a co-receptor for entry of HIV-1 and HIV-2 into cells.<sup>1-5</sup>



**Source:** Recombinant monoclonal VHH (Llama glama), purified from *S.cerevisiae* using affinity chromatography. Immunization with CXCR4-containing nanodiscs and cells. Phage-display selection on captured CXCR4-containing lipoparticles with total elution.<sup>5</sup>

**Specificity:** Q84 and Q85 bind to the extracellular part of human CXCR4 and compete for CXCL12 binding.<sup>5,6</sup>





**Formulation:** 0.2  $\mu$ m filtered solution in PBS.

**Mol. Weight:** 14.4 kDa  
**Ext. Coeff. ( $\epsilon$ ):** 24535  
**A<sub>280</sub> at 1g/L:** 1.7

**Storage:** Shipped on blue ice. Store at 4 °C or -20 °C (aliquots). Addition of 0.02% sodiumazide is optional.

**Applications:** ELISA, IF, antagonism

**Examples:**



Binding of Q85 to CXCR4 in immobilized lipoparticles in ELISA, to CXCR4 on Jurkat cells in FACS or to CXCR4-YFP in HEK293T cells in IF. Docking of a predicted model of Q85 to CXCR4 (PDB ID 3ODU).

## References:

- 1 Bleul et al. (1996) *Nature* 382, 829-833
- 2 Gonzalo et al. (2000) *J Immunol* 165, 499-508
- 3 Domanska et al. (2004) *Eur J Cancer* 49, 219-230
- 4 Deng et al. (1996) *Nature*, 381, 661-666
- 5 Jahnichen et al. (2010) *PNAS*, 107, 20565-20570
- 6 van Hout et al. (2018) *Biochem Pharmacol.* 158, 402-40127